US EditionAses Decision that Excludes Anti-Obesity Therapies From the Vital Plan Coverage Is Questioned
4 Articles
4 Articles
The determination of the public corporation, which enters into force on 1 January, was given days after WHO supported the use of these weight loss drugs.
For the first time, the Oms publishes guidelines on the use of GLP-1 drugs in the treatment of obesity, recognised as chronic and recurrent disease. Obesity affects more than one billion people worldwide. The World Health Organization has published its first guidelines on the use of glucagon-like peptide-1 therapies (Glp-1) for the treatment of obesity as chronic and recurrent disease. Obesity alarm, the Oms launches the first guidelines on GLP-…
According to WHO, more than a billion people in the world live with obesity, a condition that was linked to 3.7 million deaths in 2024. Obesity is a key factor in the development of heart disease, type 2 diabetes and some types of cancer.
The World Health Organization (WHO) presented this week its first directive on the use of glucagon-1-like peptide therapies, known as GLP-1, to treat obesity as a chronic disease. The measure marks a historic change in international policy on this condition, affecting more than one billion people and associated with 3.7 million deaths in 2024. WHO noted that if not acting urgently, the number of people with obesity is projected to double by 2030.
Coverage Details
Bias Distribution
- 100% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
